KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Gains from Investment Securities (2020 - 2026)

AbCellera Biologics filings provide 7 years of Gains from Investment Securities readings, the most recent being -$2.4 million for Q1 2026.

  • Quarterly Gains from Investment Securities fell 7.41% to -$2.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Mar 2026, up 139.0% year-over-year, with the annual reading at $3.3 million for FY2025, N/A changed from the prior year.
  • Gains from Investment Securities hit -$2.4 million in Q1 2026 for AbCellera Biologics, up from -$3.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $27.7 million in Q3 2024 and bottomed at -$35.9 million in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $273913.5, with a median of $2.5 million recorded in 2022.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 20192.29% in 2022 before it crashed 1132.42% in 2024.
  • AbCellera Biologics' Gains from Investment Securities stood at -$23.1 million in 2022, then surged by 115.04% to $3.5 million in 2023, then crashed by 1132.42% to -$35.9 million in 2024, then surged by 90.09% to -$3.6 million in 2025, then surged by 33.14% to -$2.4 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Gains from Investment Securities are -$2.4 million (Q1 2026), -$3.6 million (Q4 2025), and $6.2 million (Q3 2025).